Mass Drug Administration (MDA) is regarded as a potential strategy for locally interrupting transmission of human malaria under specific circumstances. However, insights on how MDA affects the eco-evolutionary dynamics of different Plasmodium species are not well known. We provide a computational model where the ecologically explicit life cycle of the parasite is implemented. Since the parasite inhabits two different ecological niches -human host and the mosquito -it undergoes different selection pressures during its reproduction. We use the model to perform an evolutionary analysis of the dynamics of resistance alleles under atovaquone, chloroquine and combined atovaquone-chloroquine drug treatments. Our study shows how the reduced viability of resistant parasites in the mosquito affects the spread of resistance and transmission interruption in treated human populations. Overall, results confirm that the disadvantage of drug-resistant genotypes in the mosquito vector is a good tool to achieve malaria control goals under MDA programmes.
Organisation as a potential strategy for locally interrupting transmission of human 3 malaria in isolated low transmission areas [1] . Research studies show that resistant 4 strains of the pathogen have a reproductive disadvantage in mosquitoes: mutant zygotes 5 have low viability and often cannot complete their life cycle. Here we analyse how MDA mitochondrial genome encodes the cytB gene and a single point mutation confers a high 48 level of drug resistance [16] . However, the parasites which carry this resistant allele are 49 reported to be unviable in the sexual stage of the parasite occurring in the mosquito, 50 resulting in a promising mechanism for resistance management [7, 17] . Chloroquine acts 51 during the erythrocytic growth of the parasite [18, 19] . Mutations of the 52 nuclear-encoded Chloroquine Resistance Transporter gene (PfCRT) play a significant 53 role in the widespread global resistance to this drug and other members of the antifolate 54 class [20] . Parasites with the resistant allele K76T have been reported to have an up to 55 9-fold fitness reduction compared to the wild-type in the mosquito life cycle stage [8, 21] . 56 This disadvantage, however, has not stopped the spread of chloroquine resistance in the 57 field [22] [23] [24] . Computationally, we compartmentalise the life cycle of the parasite and implement it 71 into a mechanistic model according to its biological stages: exoerythrocytic growth, 72 erythrocytic growth, gamete formation and transmission, fecundation and zygote 73 selection and sporozoite formation ( Fig. 1 ). This allows us to separate processes in the 74 host and the vector and apply different selective pressures for resistant and susceptible 75 parasite in different compartments. The parasite reproduces in each compartment, in 76 discrete time, with exponential growth and multinomial sampling. Eco-evolutionary 77 dynamics occur at two levels: within-cycle ( Fig. 2) , following each stage in days as a 78 time unit, and between multiple simultaneous cycles, referred as population 79 transmission events ( Fig. 3 ). After each transmission event, parasite population is 80 updated. Details of the computational and mathematical implementation are explained 81 in the Methods section. 82 We assume an isolated island with a constant population of 100,000 mosquitos (no 83 seasonality), reproducing in synchrony without overlapping generations. Each mosquito 84 is infected with parasites in the sporozoite form, ready to be injected to human hosts. 85 The initial sporozoite rate, percentage of female mosquitoes with infective sporozoites in 86 their salivary glands, is assumed for simulations to be 100%. This exceeds all field 87 estimates from even very high transmission areas which rarely peak above 15%.
88
However, we chose this maximal value as it provides a better appreciation of the model 89 dynamics across the full range of possible values. 90 We do not model resistance allele emergence but instead assume that resistance 91 alleles for both drugs in question already exist at appreciable frequencies in the 92 Plasmodium population (0.1 each). This could realistically arise where one or both of 93 the drugs were used in the area before MDA intervention. For one of the drugs, 94 atovaquone, resistance is conferred by an allele of the maternally inherited 95 mitochondrial genome [7] , while the second drug, chloroquine, is via mutations in the 96 nuclear genome [20] . This dictates that during segregation of both alleles during sexual 97 reproduction double resistant genotypes are generated at a much higher frequency than 98 if recombination between nuclear alleles was necessary.
99
While the viability of resistant alleles in mosquitos is the phenomena we are most 100 focused on elucidating the impact of, we have relaxed the intensity of the effect relative 101 to the published estimates. This allows for the possibility that published estimates may 102 represent the more extreme end of possible values for viability in the field.
103
Consequently, for illustration of the model, the viability in mosquitoes of atovaquone 104 resistant alleles is increased to 0.05 (from non-viable in [7] ), while for 105 chloroquine-resistant alleles viability is set to 0.3 (see SI). 106 We do make the simplifying assumption that each human bitten by mosquitoes is 107 initially uninfected regardless of their history or whether they are subject to drug treatment. The percentage coverage of humans administered is studied with the values 109 25% (low), 50% (medium), 75% (high) and 100% (full), where high and full coverage are 110 considered MDA scenarios.
111
Given the set of parameters and the justifications for their ranges, we proceed with 112 the computational model. We estimate quantities of interest such as the extinction of 113 the parasite, the rise of resistance and the impact of the drug courses when 114 administered with different population coverage.
115

Results
116
Ten consecutive transmission events (non-overlapping mosquito generations) are 117 simulated for different treatment scenarios (drug regime and population coverage).
118
After each transmission event we record the genotype frequencies (evolutionary 119 dynamics), size of the population of parasites (ecological dynamics) and the number of 120 extinctions in humans and mosquito vectors. We perform 100 realisations of the 121 complete process to account for the stochasticity in the parasite lifecycle. Results show presence of the wild-type parasite strain after ten transmission events in 125 all treatments for low (25%), medium (50%) and high (75%) coverage; however, full 126 (100%) drug coverage provokes the resistant strains to outcompete the sensitive strains 127 for all drug regimes ( Fig. 4 ). When comparing atovaquone and chloroquine, we observe 128 that the difference in the viability value (for atovaquone, 0.05; for chloroquine, 0. Overall, low levels of viability result in a stronger selective pressure than drug 146 treatment under partial drug coverage, preventing the resistant strains to spread.
147
Chloroquine resistance, which has more viability, can remain for longer in the parasite 148 population than atovaquone resistance. In contrast, full drug coverage reverses the To interpret the results from evolutionary dynamics, we need to understand the 155 variations in the ecological dynamics. When studying the parasite population size, we 156 observe that the exponential decay of the pool size increases in accordance to the drug 157 coverage and that its slope value depends on the drug regime ( Fig. 5 ). The rate of 158 population decay for low and medium treatment is similar for all the single and 159 combined drug regimes: by the end of the 10th event, population size is reduced to 160 < 10 5 with low drug coverage and < 10 3 for medium drug coverage.
161
For high population coverage, the first transmission interruption occurs for 162 atovaquone and the combined atovaquone-chloroquine regimes (before the 9th 163 transmission event) ( Fig. 6 ). For chloroquine, transmission interruption happening in 164 the 10th transmission event is the most common scenario. However, full coverage 165 reduces the population size rapidly ( Fig. 5 ), interrupting transmission in the 4th event 166 for single atovaquone and the 3rd event for combined atovaquone-chloroquine treatment 167 ( Fig. 6 ). For chloroquine, transmission interruptions occur similarly in high and full 168 drug coverage, being the most frequent event of interruption in full coverage ( Fig. 6 ).
169
In general, ecological dynamics show that there is little difference in the time of 170 transmission interruption between the single atovaquone and the combined 171 atovaquone-chloroquine treatment, especially when considering the variation caused by 172 stochastic effects. Results are similar for the different drug regimes when the treatment 173 is administrated to 75% of the population. For all drug regimes, low and medium drug coverage provoke more extinctions in the 185 human host than in the vector, due to the high frequency of wild-type parasites. High 186 population coverage with a single drug shows a similar number of extinctions in the two 187 locations, with chloroquine regime showing more extinctions in the mosquito. Full 188 coverage shows, for single drug regimes, more extinctions in the mosquito than in the 189 human. When observing the double drug regime, instead, the number of extinctions in 190 humans is greater than in mosquitos for all drug coverages ( Fig. 7a ).
191
From a medical perspective, the goal of drug efficiency is to prevent infection in 192 human individuals. A proxy for efficiency would be the number of parasite extinctions 193 in human hosts along the ten transmission events ( Fig. 7b ). Because of the differences 194 in drug coverage, we observe the extinctions relative to the population that receives efficient treatment along all the events. In the first event, all drug coverages have the 201 same efficacy because of the initial genotype frequencies, and only differing between 202 drug regimes. The double-drug regime has more efficacy because it can eliminate more 203 parasites than the single-drug regimes. 204 However, along the transmission events, the genotype frequencies change according 205 to the evolutionary dynamics and this affects the efficacy. Drug coverage scenarios that 206 favour the prevalence of sensitive-strains show more efficacy. Besides, the ecological 207 dynamics also influence the treatment efficacy: when the population size is big, more 208 humans get infected and the treatment becomes useful for more individuals. Thus, 209 despite the similar frequencies of sensitive strain that low and high coverage of 210 atovaquone have, treatment loses efficacy in high coverage because the low number of 211 existing parasites. For full coverage, the treatment is very efficient in the first event, but 212 the spread of resistant strains stops the direct effect of human healing of the treatment. 213 This phenomena is accentuated in the double-drug regime.
214
Discussion and conclusion 215
The finding by Goodman et al. [7, 17] that maternally inherited resistance alleles in 216 malaria plasmodia to the drug atovaquone show limited viability in mosquitoes, led 217 them to speculate that this could be exploited to limit the increase in frequency of such 218 alleles in circumstances where the drug in question is widely employed, e.g. MDA. By 219 developing and implementing our life cycle based model we have confirmed that drug 220 resistance management is indeed feasible (Fig. 4) , even in MDA programmes where 221 70% of the human population may be receiving the drug.
222
Given that globally, best practice requires the use of drug combinations for malaria 223 treatment and prophylaxis, we chose to incorporate into our model a second drug. In 224 doing so, we selected chloroquine, which in common with the vast majority of malaria 225 drugs has resistance alleles encoded on the plasmodia nuclear chromosomes. Moreover, 226 some disadvantage in the reproduction of chloroquine-resistant parasites has been 227 reported in previous literature [8, 21] .
228
In our model, we studied the effect of antagonistic selection pressures by including 229 fitness parameter estimates for atovaquone and chloroquine. However, any combination 230 of drugs with resistance alleles with suitable patterns of inheritance could be modelled 231 across a wide range of parameter values. It is essential to note that in our modelled 232 scenarios, resistance alleles are already initially present. The rationale for not 233 incorporating the emergence of resistance is appropriate as there is no evidence that 234 MDA programs increase the probability of resistance alleles arising, beyond that 235 resulting from other patterns of drug administration [4, 6] . 236 The insights of our MDA model relate to the change in frequencies over time of 237 drug-resistant genotypes and impact on the goal of timely interruption of malaria 238 transmission in an isolated population. The evolutionary findings of our model confirm 239 the intuitive and established [25] result, that where resistance alleles are present in the 240 parasite population, low (25%) and medium (50%) levels of population drug coverage 241 should not act to substantially increase resistance frequency. However, at higher 242 coverage treatment regimes ≥75% the low viability of resistance alleles for one drug in 243 the mosquito vector can usefully manage the rise of resistance alleles for another drug. 244 The comparison between single and double drug treatment shows little or no The atovaquone treatment outcomes turn out similar to the combined 251 atovaquone-chloroquine regime, suggesting a single drug with very low viability would 252 be sufficient for MDA programmes. This result is observed even under our conservative 253 (but untested) assumption that the mosquito viability disadvantage is multiplicative for 254 the double resistant plasmodia individuals.
255
With respects to the ecological findings of the model, we are interested in the 256 capacity to achieve local interruption of malaria transmission. Even starting from an 257 unrealistically high sporozoite rate of 100% where all the female mosquitoes initially are 258 infective (1 to 2 orders of magnitude higher than observed in field studies in high 259 transmission areas), eliminating transmission is still possible where a large proportion of 260 the human population consents to continuous drug treatment (Figs. 5 and 6). The 261 transmission interruption occurs within a much smaller number of transmission events 262 in the scenarios where a drug with a substantial reduction in resistant genotype 263 mosquito viability is employed -i.e. more than two times faster for atovaquone than for 264 chloroquine treatment. (Fig. 6 ). As with the evolutionary dynamics, there is little 265 indication of synergy, with the combination drug treatment only marginally quicker than 266 under atovaquone alone. This is even more noticeable when we consider the variance in 267 the number of transmission events required for transmission interruption (Fig. 6 ).
268
The combined eco-evolutionary findings of the model provide insights into the 269 trade-off between the speed with which transmission interruption can be achieved and 270 the extent to which resistant genotypes, including double drug-resistant ones, rise in 271 frequency. Were it feasible to treat 100% of the population with either atovaquone or a 272 combination of drugs, resistant alleles would probably rise to high frequency (Fig. 4) . 273 This would not prevent the MDA driven decline in the number of plasmodia circulating 274 in the pool (Fig. 5 ) nor the corresponding reduction in the number of cases of human 275 malaria ( Fig. 7) . On the other hand, it would mean that medical interventions to treat 276 patients would likely not be able to rely on the effectiveness of any of the classes of 277 drugs employed in the MDA. Consequently, in the attempt to eliminate transmission 278 rapidly, it would be wise to make alternative drugs available to medical services that are 279 likely to retain their effectiveness for case treatments. If a considerably slower path to 280 transmission interruption is sought, with a population drug coverage of 75% (Figs. 5,6), 281 high frequency of resistance can be avoided by using atovaquone or a combination of 282 both drugs (Fig. 4 ). Further strategies could be investigated using the model, such as 283 drug cycling or purposely changing drug population coverage during the treatment 284 programme.
285
While our model can confirm many of the hoped-for predictions stemming from the 286 observation of reduced viability of drug-resistant genotypes in the mosquito vector, we 287 do not support a substantial degree of synergy stemming from a combination of 288 resistance alleles that share this property. Consequently, it could be reasonable that an 289 MDA based on a single drug with the most suitable properties may be sufficient to 290 achieve malaria control goals. However, the history of malaria control indicates it is 291 rarely wise to rely on a single mechanism, and other factors not included in our model 292 may limit or enhance the importance of the factors highlighted here. For example, 293 within-human fitness costs reported for resistant parasites [26] could intensify the 294 plasmodia killing effect in humans beyond the substantial mosquito effect described here 295 (Fig. 7A ). Not explained in our model is the fact that chloroquine resistance alleles, 296 despite inferred viability loss in mosquitoes, remain at appreciable frequencies around 297 the world [27] . The model can thus be extended to capture more realistic scenarios, 298 alternatively, it might be possible that genotype-specific estimates of viability in 299 mosquitoes are to some degree context-dependent. Scenarios include the possibility that 300 the estimated viability disadvantages of resistance alleles may be smaller than 301 estimated [28] or may even be selected to decrease during a long-term MDA effort. The model, as described in this paper, follows each step of the life cycle of the 303 Plasmodium using available parameter estimates [29] . We envision that the model will 304 provide a convenient basis for further elaborations. Complex models (e.g. including 305 epidemiology, spatio-temporal heterogeneity in drug coverage) would then move towards 306 informing the role MDA could play in leveraging genotypic viability differences towards 307 the goal of eliminating malaria within a generation.
308
Methods
309
We compartmentalise the life cycle of the parasite according to its biological stages and 310 implement it into a mechanistic computational model (Fig. 1) . The parasite reproduces 311 in each compartment, in discrete time, with exponential growth and multinomial 312 sampling. Eco-evolutionary dynamics occur at two levels: within-cycle, following each 313 stage in days as the time unit, and between multiple simultaneous cycles, referred as 314 population transmission events. Importantly, all resistant genotypes are present in the 315 population from the beginning and mutation is not considered. Host-vector transmission and parasite growth happen continuously in mixed populations 318 of humans and mosquitoes carrying Plasmodium. In our model, the life cycle starts with 319 a mosquito-to-human transmission of the parasite. Then, the cycle splits into stages, 320 which work as sequential compartments receiving a parasite input and return an output 321 that goes on, until the cycle ends. Genetically, we define a mtDNA haploid locus for 322 atovaquone resistance with the resistant A and susceptible a alleles. A nDNA locus for 323 chloroquine resistance is haploid in the asexual phase and diploid in the sexual phase.
324
The resistant C and susceptible c alleles are for chloroquine. For those stages in which 325 the parasite is haploid, the parasite vector contains n i , whereas for those in which is 326 diploid, contains z i of the possible combinations shown below: 327 C c A n 1 n 3 a n 2 n 4
CC Cc cc
The total number of parasites as input and output for each compartment has been 329 adjusted to the values shown in [29] , in which the author reviewed and summarised 330 quantitative data from different malaria studies. Dynamics within one cycle are shown 331 in Fig. 2 . where the wild type is the most common genotype.
337
Exoerythrocytic growth (Day 0 to 5)
338
Once in the human host, sporozoites are directed into the liver, where they form 339 schizonts and release merozoites into the blood. For sporozoites to reproduce, we use 340 exponential growth in discrete time:
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where n i is number of haploid genotype i with r i (j, k) as its growth rate. This equation 342 is used in all life cycle stages, that involve asexual reproduction. The growth rate of the 343 genotype i depends on the life cycle stage j and the drug scenario k. Without drug 344 selection, all genotypes i have the same growth within each stage r i (j, k) = b j . During 345 the exoerythrocytic growth, b j = 5, so each sporozoite replicates into five sporozoites 346 per day. The population is updated until t = 5 [29] .
347
Erythrocytic growth (Day 5 to 13)
348
In the erythrocytic phase, schizonts generate merozoites which infect erythrocytes in the 349 blood. Schizonts replicate in four cycles of two days. For reproduction of the parasite in 350 this stage, we use exponential growth (Eq. (1)). Here population is updated every two 351 time-steps (n i (t + 2)) until t = 13 with a birth rate b j = 16 [29] .
352
Gamete formation and human-mosquito transmission (Day 13 to 23)
353
Gametocytes are produced with an efficiency of = 0.0048 [29] . Thus, the population 354 update is the product of the current population and the efficiency rate:
Since the population size is large, stochastic effects are ignored, and genotype 356 frequencies do not vary. However, gametocytes are the first step of the sexual 357 reproduction in Plasmodium: female and male. The female:male ratio of gametocytes is 358 4 : 1 [29] , an important feature for fecundation. To implement sex differentiation, we 359 multiply our population per ratio proportion:
Consequently, our parasite population consists of eight types depending on sex and 361 genotype. For these gametocytes to mate, a mosquito needs to bite the infected human 362 and pick up both male and female gametocytes, as the fecundation takes place in the 363 mosquito gut. The mosquito bite takes typically N = 48 gametocytes [29] implemented 364 through multinomial sampling. This process introduces an ecological bottleneck for the 365 parasite population, with drift affecting the genotype frequencies.
366
The parasite merozoites continue to grow and infect erythrocytes causing the disease. 367 However, here, we keep our focus on the parasite forms that follow the complete life 368 cycle.
369
Fecundation and zygote selection (Day 23 to 25)
370
In the mosquito gut, gametocytes form zygotes. Male gametocytes are the limiting 371 factor due to the biased sex ratio. We implement sampling without replacement to 372 match male and female gametocytes, and we obtain Z = N m diploid zygotes, classified 373 in six genotypes. Importantly, in the zygote genotypes, the atovaquone locus remains 374 haploid and corresponds to the female allele, following mtDNA maternal inheritance.
375
The resulting zygotes Z are subject to viability selection. These probability of The zygotes in the mosquito gut mature into oocysts and ookinetes progressively, finally 386 forming sporozoites and going back to haploid asexual form. In the model, the mapping 387 from diploid to haploid follows:
where {x, y} = 2 for the matching homozygote and {x, y} = 1 for the matching At the appropriate stages in the life cycle, we introduce atovaquone and chloroquine.
414
Atovaquone affects the parasites before and during the liver stage, that is, during the 415 exoerythrocytic growth. Chloroquine acts on the intra-erythrocytic parasites, that is, 416 during erythrocytic growth. As in these stages, reproduction follows discrete exponential 417 growth; we can include the drug as suppressed growth rate for the susceptible genotypes. 418 The growth rate r k ij defined in Eq. 1 can be describe d now as:
where in the presence of drugs the fitness of genotype i is w i (j, k) = 0.1 if the i is We consider extinction the scenario in which the initial inoculum of N = 10 parasites is 430 reduced to N = 0, either in the human or in the mosquito. In the absence of drugs, the 431 parasite can go extinct in the mosquito: under viability selection, all zygotes except for 432 the wild-type genotype have a probability of survival less than 1, meaning that if by phase, it has not prevented the spread of resistance. Here we test different levels of 447 viability for the parasite genotypes with the resistance mutation, to be compared in the 448 main results with the atovaquone-resistant parasites (with a very low viability of 0.05). 449 The values tested in this section are the following: 0.05, 0.11, 0.3, 0.5, 1.0 ( Fig. 8 ).
450
The parameter range of viability is from 0 to 1; thus, in the lower range we choose 0.05 451 as equivalent to the atovaquone-resistance viability and we choose the upper extreme 1 452 in which there is no disadvantage. Because the paper [8] reports a 9-fold disadvantage 453 of the resistant parasites, the value 0.11 is also tested. In the intermediate range, 0.3 454 and 0.5 are chosen arbitrarily.
455
Given the known spread of chloroquine resistance, the final choice corresponds to the 456 smallest value which shows resistance maintenance in medium and high levels of drug hosts. The mosquito bites the human and injects sporozoites, which are directed to the liver. In the liver schizonts are formed which then release merozoites. These merozoites go into the blood stream and infect erythrocytes. In the erythrocytes, merozoites mature into trophozoites and form schizonts which release merozoites again. Some of these merozoites create gametocytes, females and males in a ratio 4:1. The mosquito, when biting the infected human, takes up some gametocytes, and in its gut fecundation occurs resulting in zygote formation. The viable zygotes develop into motile ookinetes, which attach to the gut wall, mature into oocyst, and release sporozoites. These sporozoites migrate to the salivary glands, ready to be injected again in the human host in the next cycle. b) Simplified steps of life cycle in human (yellow) and mosquito (grey) hosts. For modelling purposes, we consider the life cycle starting from a pool of sporozoites which comes from the multiple mosquitoes biting humans. Then, the steps followed are: (i) exoerythrocytic growth, (ii) erythrocytic growth, (iii) gamete formation and transmission, (iv) fecundation and zygote selection, and (v) sporozoite formation. After these phases, the sporozoites formed become part of the pool of sporozoites and the cycle starts again. Mean genotype frequencies for the parasite population at the beginning of each event are shown as cumulative bars. All plots correspond to chloroquine treatment scenarios, with low (25%), medium (50%), high (75%) and full (100%) population coverage. All plots start with the initial frequencies for wild-type (grey), single atovaquone resistant (red), single chloroquine resistant (blue), double resistant (yellow). The sum of all genotype mean frequencies has been normalised to 1 for all transmission events in which parasites were present. Blank events correspond to transmission interruption.
